Close Menu

NEW YORK – Qiagen said on Thursday that it expects second quarter net sales to increase 18 percent to 19 percent year over year at constant exchange rates (CER), exceeding the outlook of 12 percent growth it provided in May.

Based on the expected percentage growth range and sales of $381.6 million in Q2 2019, Q2 sales would be $450.3 million to $454.1 million. On average, analysts were expecting Q2 revenues of $413.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.